Idiopathic pulmonary fibrosis and cancer: do they really look similar?
Idiopathic pulmonary fibrosis and cancer: do they really look similar?
复制标题
特发性肺纤维化和癌症：它们看起来真的相似吗？
DOI：
10.1186/s12916-015-0478-1
复制
发表时间：
2015-09-24
期刊：
影响因子：
9.3
通讯作者：
Vancheri C
中科院分区：
文献类型：
--
作者：
Vancheri C
这篇评论文章的目的是了解特发性肺纤维化 (IPF) 的临床和致病特征在多大程度上可以被视为与癌症相似。事实上，IPF 与癌症具有共同的危险因素、低生存率，最重要的是，表观遗传和遗传改变、microRNA 的异常表达、细胞和分子异常以及类似信号通路的激活。这两种疾病之间的致病联系可能会产生许多实际后果。它可以利用癌症生物学知识提高我们对 IPF 的理解。此外，对相似致病途径的认识也可能鼓励使用抗癌药物来治疗 IPF。尼达尼布是一种酪氨酸激酶受体抑制剂，最初是为癌症而开发的，由于观察到这些受体在 IPF 中也异常激活，最近已被批准用于 IPF 的治疗。将 IPF 作为一种类癌疾病的观点可能会提高我们对这种疾病发病机制的理解，也为重新定位 IPF 癌症药物开辟新的前景。此外，它还可能提高公众、政治和医疗保健层面对这种可怕疾病的认识水平。
The aim of this opinion article is to understand to what extent idiopathic pulmonary fibrosis (IPF) can be considered, in its clinical and pathogenic features, similar to cancer. Indeed, IPF has common risk factors with cancer, a low survival, and, most importantly, epigenetic and genetic alterations, abnormal expression of microRNAs, cellular and molecular aberrances, and the activation of similar signalling pathways. The pathogenic link between the two diseases may have a number of practical consequences. It may improve our understanding of IPF drawing on cancer biology knowledge. In addition, the recognition of similar pathogenic pathways may also encourage the use of cancer drugs for the treatment of IPF. Nintedanib, an inhibitor of tyrosine kinase receptors initially developed for cancer, has been recently approved for the treatment of IPF thanks to the observation that these receptors are also abnormally activated in IPF. The vision of IPF as a cancer-like disease may improve our understanding of the pathogenesis of this disease also opening new scenarios for repositioning cancer drugs for IPF. In addition, it may increase the level of awareness towards this dreadful disease at the public, political, and healthcare level.